| 1 | inhaled | 6,234 |
| 2 | intranasal | 1,329 |
| 3 | nebulized | 658 |
| 4 | nebulised | 332 |
| 5 | aerosolized | 264 |
| 6 | inhaling | 113 |
| 7 | 1:100,000 | 105 |
| 8 | 1:200,000 | 79 |
| 9 | neuroactive | 78 |
| 10 | shenqi | 49 |
| 11 | non-oral | 39 |
| 12 | extrafine | 35 |
| 13 | anabolic-androgenic | 34 |
| 14 | inhalative | 31 |
| 15 | omecamtiv | 26 |
| 16 | aerosolised | 18 |
| 17 | extra-fine | 18 |
| 18 | naproxen/esomeprazole | 17 |
| 19 | inhalatory | 13 |
| 20 | 17-alpha | 12 |
| 21 | 1:80,000 | 12 |
| 22 | 9-cis | 12 |
| 23 | bufei | 12 |
| 24 | ring-fused | 9 |
| 25 | bolus-dose | 8 |
| 26 | 1:50,000 | 7 |
| 27 | intrabursal | 7 |
| 28 | nonpreserved | 7 |
| 29 | 2,2-diphenyl-1-picryl | 6 |
| 30 | cfc-free | 6 |
| 31 | isosmotic | 6 |
| 32 | superpotent | 6 |
| 33 | 17-α | 5 |
| 34 | chongcao | 5 |
| 35 | enhanced-affinity | 5 |
| 36 | hpol | 5 |
| 37 | hydrofluoroalkane-propelled | 5 |
| 38 | matrix-type | 5 |
| 39 | oral-loaded | 5 |
| 40 | standard-titration | 5 |
| 41 | subantimicrobial-dose | 5 |
| 42 | 0.075-mg | 4 |
| 43 | 1:100000 | 4 |
| 44 | ad35-grin/env | 4 |
| 45 | aminoglycoside/ | 4 |
| 46 | anti-progestin | 4 |
| 47 | carbon-supported | 4 |
| 48 | intra-nasal | 4 |
| 49 | itm/iv | 4 |
| 50 | iv-administered | 4 |
| 51 | oral/intravenous | 4 |
| 52 | premedication+in | 4 |
| 53 | uv-only | 4 |
| 54 | /inhaled | 3 |
| 55 | 0.25mg/kg | 3 |
| 56 | 1'-hydroxy | 3 |
| 57 | 1:100.000 | 3 |
| 58 | 1:80000 | 3 |
| 59 | anesthesiologist-managed | 3 |
| 60 | cysteine-containing | 3 |
| 61 | desflurane-based | 3 |
| 62 | endoscopist-administered | 3 |
| 63 | poly-n-acetyl | 3 |
| 64 | rapid-and | 3 |
| 65 | self-injectable | 3 |
| 66 | sometribove | 3 |
| 67 | subdissociative-dose | 3 |
| 68 | tci-delivered | 3 |
| 69 | triaromatic | 3 |
| 70 | trimethoprim- | 3 |
| 71 | ultrapotent | 3 |
| 72 | β2-agonist/inhaled | 3 |
| 73 | -o-xylosyl | 2 |
| 74 | 0.25-mg | 2 |
| 75 | 1-hydroxy | 2 |
| 76 | 150μmol/l | 2 |
| 77 | 16β-hydroxylation | 2 |
| 78 | 17-keto | 2 |
| 79 | 17-ketogenic | 2 |
| 80 | 1:200.000 | 2 |
| 81 | 1:200000 | 2 |
| 82 | 40/4.5 | 2 |
| 83 | 5c21 | 2 |
| 84 | 75μg | 2 |
| 85 | an1/a20 | 2 |
| 86 | antiprogestagen | 2 |
| 87 | bioavail | 2 |
| 88 | chlorofluorocarbon-propelled | 2 |
| 89 | costs.inhaled | 2 |
| 90 | fentanyl/ | 2 |
| 91 | helene | 2 |
| 92 | high-potent | 2 |
| 93 | hydroquinone-containing | 2 |
| 94 | inhaled/oral | 2 |
| 95 | l/v | 2 |
| 96 | lipid-emulsion | 2 |
| 97 | low-to-medium-dose | 2 |
| 98 | microfine | 2 |
| 99 | multiple-course | 2 |
| 100 | non-anaesthesiologist | 2 |
| 101 | non-anaesthesiologist-administered | 2 |
| 102 | non-epinephrine | 2 |
| 103 | peritendonous | 2 |
| 104 | placebo/ | 2 |
| 105 | reninintracellular | 2 |
| 106 | rxr-selective | 2 |
| 107 | s=3 | 2 |
| 108 | tissue-cultured | 2 |
| 109 | tramadol/ | 2 |
| 110 | umuline | 2 |
| 111 | xiongbai | 2 |
| 112 | 'staccato | 1 |
| 113 | -3β-hydroxy | 1 |
| 114 | -agonist/inhaled | 1 |
| 115 | -o-apiosyl | 1 |
| 116 | -perioperative | 1 |
| 117 | 0.2-μg/kg/min | 1 |
| 118 | 0.3ppm | 1 |
| 119 | 0.5mg/kg/min | 1 |
| 120 | 1'-oh | 1 |
| 121 | 1,1,3,3-tetramethyl | 1 |
| 122 | 1,2,3-triazolium-based | 1 |
| 123 | 1-μg/kg | 1 |
| 124 | 1.5μg | 1 |
| 125 | 1/100.000 | 1 |
| 126 | 1/v | 1 |
| 127 | 10-60-mg | 1 |
| 128 | 150-µg | 1 |
| 129 | 15222 | 1 |
| 130 | 16-heterosubstituted | 1 |
| 131 | 1:100.100 | 1 |
| 132 | 1:2,000 | 1 |
| 133 | 2+2l | 1 |
| 134 | 2-ohe-derived | 1 |
| 135 | 200-mcg/d | 1 |
| 136 | 25-week-old | 1 |
| 137 | 3,4-d. | 1 |
| 138 | 3.3-mg | 1 |
| 139 | 35-mcg | 1 |
| 140 | 350ng | 1 |
| 141 | 3mix-mp | 1 |
| 142 | 3β-hydroxy-5-ene | 1 |
| 143 | 4'-o-glucosyl | 1 |
| 144 | 5,10,15,20- | 1 |
| 145 | 5-c21 | 1 |
| 146 | 50iu | 1 |
| 147 | 5β- | 1 |
| 148 | acylureido-penicillins | 1 |
| 149 | alkaloide | 1 |
| 150 | alpha/beta-agonist | 1 |
| 151 | alphaxaloneand | 1 |
| 152 | aminomonosaccharide | 1 |
| 153 | anabolic/androgenic | 1 |
| 154 | anti-meth/amp | 1 |
| 155 | anti-tnf-α- | 1 |
| 156 | anti-xerostomic | 1 |
| 157 | antiandrogenous | 1 |
| 158 | antimicrobial-dose | 1 |
| 159 | applicating | 1 |
| 160 | approach-short-term | 1 |
| 161 | auto-injectable | 1 |
| 162 | beef-flavored | 1 |
| 163 | beta-2-selective | 1 |
| 164 | beta2-agonist/inhaled | 1 |
| 165 | biorelease | 1 |
| 166 | blp25 | 1 |
| 167 | bpo-containing | 1 |
| 168 | bronchodilator/inhaled | 1 |
| 169 | broncholitic | 1 |
| 170 | care-co-formulated | 1 |
| 171 | caveolin-3-dependent | 1 |
| 172 | cefepime/ | 1 |
| 173 | cephalexine | 1 |
| 174 | cholestane | 1 |
| 175 | cholestane-3 | 1 |
| 176 | ck2-antagonist | 1 |
| 177 | co-regulator | 1 |
| 178 | criteria.inhaled | 1 |
| 179 | cyp3a4-catalyzed | 1 |
| 180 | d2-antagonist | 1 |
| 181 | dehydropydine | 1 |
| 182 | depot/long-acting | 1 |
| 183 | essaying | 1 |
| 184 | estrone:16α-hydroxy | 1 |
| 185 | eta-antagonist | 1 |
| 186 | everolimus-facilitated | 1 |
| 187 | every-two-week | 1 |
| 188 | ezh2-targeting | 1 |
| 189 | fixed-dosed | 1 |
| 190 | flexible-dosage | 1 |
| 191 | fortifed | 1 |
| 192 | gallium-doped | 1 |
| 193 | generic-original | 1 |
| 194 | glycosylphosphatidyl | 1 |
| 195 | glycozaminoglycans | 1 |
| 196 | heliox®-driven | 1 |
| 197 | hepatocyte-targeted | 1 |
| 198 | hf+i | 1 |
| 199 | high-bolus-dose | 1 |
| 200 | hyodemic | 1 |
| 201 | imipenem/ | 1 |
| 202 | immediate-and | 1 |
| 203 | inhaled/intranasal | 1 |
| 204 | initiator-free | 1 |
| 205 | instant-release | 1 |
| 206 | intra-mammary-administered | 1 |
| 207 | intra-testicular | 1 |
| 208 | intraoperative-intrathecal | 1 |
| 209 | islas | 1 |
| 210 | isrctn63818313 | 1 |
| 211 | jet-nebulized | 1 |
| 212 | karyopherin | 1 |
| 213 | ketamine-low-dose | 1 |
| 214 | langchuang | 1 |
| 215 | levonorgestrel/ | 1 |
| 216 | lipid-deficient/evaporative | 1 |
| 217 | lipid-normalized | 1 |
| 218 | locally-delivered | 1 |
| 219 | long-/ultra-long-acting | 1 |
| 220 | meta-analysis.when | 1 |
| 221 | methylcyclopentadienyl | 1 |
| 222 | micro-crystalline | 1 |
| 223 | midazolam/low-dose | 1 |
| 224 | mild/modest | 1 |
| 225 | mmf+ | 1 |
| 226 | mpla-adjuvanted | 1 |
| 227 | mtx+intravenous | 1 |
| 228 | multi-barrel | 1 |
| 229 | n'-dialkyl | 1 |
| 230 | nbp-stimulated | 1 |
| 231 | niacin-bound | 1 |
| 232 | non-long-acting | 1 |
| 233 | nonprescription-strength | 1 |
| 234 | nsd-nasal | 1 |
| 235 | o-linked-n-acetyl | 1 |
| 236 | of.inhaled | 1 |
| 237 | orthoclone | 1 |
| 238 | parentally-administered | 1 |
| 239 | pareteral | 1 |
| 240 | particle-inhaled | 1 |
| 241 | patient-choice-facilitated | 1 |
| 242 | pb-stabilized | 1 |
| 243 | perindopril/ | 1 |
| 244 | phenylacetyl | 1 |
| 245 | pioglitazone→exenatide | 1 |
| 246 | placebo.additional | 1 |
| 247 | pmf/ | 1 |
| 248 | polycarbonate- | 1 |
| 249 | polyenteric-coated | 1 |
| 250 | ppia+oral | 1 |
| 251 | pre-junctional | 1 |
| 252 | precesarean | 1 |
| 253 | prolonged-action | 1 |
| 254 | prrsv+pcv2 | 1 |
| 255 | q10-containing | 1 |
| 256 | qi-zhi | 1 |
| 257 | quinazoline-based | 1 |
| 258 | recemic | 1 |
| 259 | recrystallised | 1 |
| 260 | rfviii-lip | 1 |
| 261 | salm/fp+as-needed | 1 |
| 262 | same-potency | 1 |
| 263 | short-/long-acting | 1 |
| 264 | sitagliptin→exenatide | 1 |
| 265 | spun-cast | 1 |
| 266 | streptavidin- | 1 |
| 267 | studies.nebulized | 1 |
| 268 | sub-anesthetic | 1 |
| 269 | super-high-potent | 1 |
| 270 | sutcutaneous | 1 |
| 271 | sympatheticomimetics | 1 |
| 272 | t2r38-directed | 1 |
| 273 | tetrasulfide-containing | 1 |
| 274 | tomato-sourced | 1 |
| 275 | topical/systemic | 1 |
| 276 | traumatic-induced | 1 |
| 277 | treadmill-running | 1 |
| 278 | u.k.-licensed | 1 |
| 279 | ultra-laba/ | 1 |
| 280 | uvb+ | 1 |
| 281 | valmet | 1 |
| 282 | varving | 1 |
| 283 | visit/systemic | 1 |
| 284 | water-dissolved | 1 |
| 285 | zaizao | 1 |
| 286 | β-agonist/inhaled | 1 |
| 287 | μ-agonist | 1 |
| 288 | μ-opioid-antagonist | 1 |
| 289 | ≥50μg | 1 |
| 290 | ▾ | 1 |
| 1 | 'staccato | 1 |
| 2 | -3β-hydroxy | 1 |
| 3 | -agonist/inhaled | 1 |
| 4 | -o-apiosyl | 1 |
| 5 | -o-xylosyl | 2 |
| 6 | -perioperative | 1 |
| 7 | /inhaled | 3 |
| 8 | 0.075-mg | 4 |
| 9 | 0.2-μg/kg/min | 1 |
| 10 | 0.25-mg | 2 |
| 11 | 0.25mg/kg | 3 |
| 12 | 0.3ppm | 1 |
| 13 | 0.5mg/kg/min | 1 |
| 14 | 1'-hydroxy | 3 |
| 15 | 1'-oh | 1 |
| 16 | 1,1,3,3-tetramethyl | 1 |
| 17 | 1,2,3-triazolium-based | 1 |
| 18 | 1-hydroxy | 2 |
| 19 | 1-μg/kg | 1 |
| 20 | 1.5μg | 1 |
| 21 | 1/100.000 | 1 |
| 22 | 1/v | 1 |
| 23 | 10-60-mg | 1 |
| 24 | 150-µg | 1 |
| 25 | 150μmol/l | 2 |
| 26 | 15222 | 1 |
| 27 | 16-heterosubstituted | 1 |
| 28 | 16β-hydroxylation | 2 |
| 29 | 17-alpha | 12 |
| 30 | 17-keto | 2 |
| 31 | 17-ketogenic | 2 |
| 32 | 17-α | 5 |
| 33 | 1:100,000 | 105 |
| 34 | 1:100.000 | 3 |
| 35 | 1:100.100 | 1 |
| 36 | 1:100000 | 4 |
| 37 | 1:2,000 | 1 |
| 38 | 1:200,000 | 79 |
| 39 | 1:200.000 | 2 |
| 40 | 1:200000 | 2 |
| 41 | 1:50,000 | 7 |
| 42 | 1:80,000 | 12 |
| 43 | 1:80000 | 3 |
| 44 | 2+2l | 1 |
| 45 | 2,2-diphenyl-1-picryl | 6 |
| 46 | 2-ohe-derived | 1 |
| 47 | 200-mcg/d | 1 |
| 48 | 25-week-old | 1 |
| 49 | 3,4-d. | 1 |
| 50 | 3.3-mg | 1 |
| 51 | 35-mcg | 1 |
| 52 | 350ng | 1 |
| 53 | 3mix-mp | 1 |
| 54 | 3β-hydroxy-5-ene | 1 |
| 55 | 4'-o-glucosyl | 1 |
| 56 | 40/4.5 | 2 |
| 57 | 5,10,15,20- | 1 |
| 58 | 5-c21 | 1 |
| 59 | 50iu | 1 |
| 60 | 5c21 | 2 |
| 61 | 5β- | 1 |
| 62 | 75μg | 2 |
| 63 | 9-cis | 12 |
| 64 | acylureido-penicillins | 1 |
| 65 | ad35-grin/env | 4 |
| 66 | aerosolised | 18 |
| 67 | aerosolized | 264 |
| 68 | alkaloide | 1 |
| 69 | alpha/beta-agonist | 1 |
| 70 | alphaxaloneand | 1 |
| 71 | aminoglycoside/ | 4 |
| 72 | aminomonosaccharide | 1 |
| 73 | an1/a20 | 2 |
| 74 | anabolic-androgenic | 34 |
| 75 | anabolic/androgenic | 1 |
| 76 | anesthesiologist-managed | 3 |
| 77 | anti-meth/amp | 1 |
| 78 | anti-progestin | 4 |
| 79 | anti-tnf-α- | 1 |
| 80 | anti-xerostomic | 1 |
| 81 | antiandrogenous | 1 |
| 82 | antimicrobial-dose | 1 |
| 83 | antiprogestagen | 2 |
| 84 | applicating | 1 |
| 85 | approach-short-term | 1 |
| 86 | auto-injectable | 1 |
| 87 | beef-flavored | 1 |
| 88 | beta-2-selective | 1 |
| 89 | beta2-agonist/inhaled | 1 |
| 90 | bioavail | 2 |
| 91 | biorelease | 1 |
| 92 | blp25 | 1 |
| 93 | bolus-dose | 8 |
| 94 | bpo-containing | 1 |
| 95 | bronchodilator/inhaled | 1 |
| 96 | broncholitic | 1 |
| 97 | bufei | 12 |
| 98 | carbon-supported | 4 |
| 99 | care-co-formulated | 1 |
| 100 | caveolin-3-dependent | 1 |
| 101 | cefepime/ | 1 |
| 102 | cephalexine | 1 |
| 103 | cfc-free | 6 |
| 104 | chlorofluorocarbon-propelled | 2 |
| 105 | cholestane | 1 |
| 106 | cholestane-3 | 1 |
| 107 | chongcao | 5 |
| 108 | ck2-antagonist | 1 |
| 109 | co-regulator | 1 |
| 110 | costs.inhaled | 2 |
| 111 | criteria.inhaled | 1 |
| 112 | cyp3a4-catalyzed | 1 |
| 113 | cysteine-containing | 3 |
| 114 | d2-antagonist | 1 |
| 115 | dehydropydine | 1 |
| 116 | depot/long-acting | 1 |
| 117 | desflurane-based | 3 |
| 118 | endoscopist-administered | 3 |
| 119 | enhanced-affinity | 5 |
| 120 | essaying | 1 |
| 121 | estrone:16α-hydroxy | 1 |
| 122 | eta-antagonist | 1 |
| 123 | everolimus-facilitated | 1 |
| 124 | every-two-week | 1 |
| 125 | extra-fine | 18 |
| 126 | extrafine | 35 |
| 127 | ezh2-targeting | 1 |
| 128 | fentanyl/ | 2 |
| 129 | fixed-dosed | 1 |
| 130 | flexible-dosage | 1 |
| 131 | fortifed | 1 |
| 132 | gallium-doped | 1 |
| 133 | generic-original | 1 |
| 134 | glycosylphosphatidyl | 1 |
| 135 | glycozaminoglycans | 1 |
| 136 | helene | 2 |
| 137 | heliox®-driven | 1 |
| 138 | hepatocyte-targeted | 1 |
| 139 | hf+i | 1 |
| 140 | high-bolus-dose | 1 |
| 141 | high-potent | 2 |
| 142 | hpol | 5 |
| 143 | hydrofluoroalkane-propelled | 5 |
| 144 | hydroquinone-containing | 2 |
| 145 | hyodemic | 1 |
| 146 | imipenem/ | 1 |
| 147 | immediate-and | 1 |
| 148 | inhalative | 31 |
| 149 | inhalatory | 13 |
| 150 | inhaled | 6,234 |
| 151 | inhaled/intranasal | 1 |
| 152 | inhaled/oral | 2 |
| 153 | inhaling | 113 |
| 154 | initiator-free | 1 |
| 155 | instant-release | 1 |
| 156 | intra-mammary-administered | 1 |
| 157 | intra-nasal | 4 |
| 158 | intra-testicular | 1 |
| 159 | intrabursal | 7 |
| 160 | intranasal | 1,329 |
| 161 | intraoperative-intrathecal | 1 |
| 162 | islas | 1 |
| 163 | isosmotic | 6 |
| 164 | isrctn63818313 | 1 |
| 165 | itm/iv | 4 |
| 166 | iv-administered | 4 |
| 167 | jet-nebulized | 1 |
| 168 | karyopherin | 1 |
| 169 | ketamine-low-dose | 1 |
| 170 | l/v | 2 |
| 171 | langchuang | 1 |
| 172 | levonorgestrel/ | 1 |
| 173 | lipid-deficient/evaporative | 1 |
| 174 | lipid-emulsion | 2 |
| 175 | lipid-normalized | 1 |
| 176 | locally-delivered | 1 |
| 177 | long-/ultra-long-acting | 1 |
| 178 | low-to-medium-dose | 2 |
| 179 | matrix-type | 5 |
| 180 | meta-analysis.when | 1 |
| 181 | methylcyclopentadienyl | 1 |
| 182 | micro-crystalline | 1 |
| 183 | microfine | 2 |
| 184 | midazolam/low-dose | 1 |
| 185 | mild/modest | 1 |
| 186 | mmf+ | 1 |
| 187 | mpla-adjuvanted | 1 |
| 188 | mtx+intravenous | 1 |
| 189 | multi-barrel | 1 |
| 190 | multiple-course | 2 |
| 191 | n'-dialkyl | 1 |
| 192 | naproxen/esomeprazole | 17 |
| 193 | nbp-stimulated | 1 |
| 194 | nebulised | 332 |
| 195 | nebulized | 658 |
| 196 | neuroactive | 78 |
| 197 | niacin-bound | 1 |
| 198 | non-anaesthesiologist | 2 |
| 199 | non-anaesthesiologist-administered | 2 |
| 200 | non-epinephrine | 2 |
| 201 | non-long-acting | 1 |
| 202 | non-oral | 39 |
| 203 | nonprescription-strength | 1 |
| 204 | nonpreserved | 7 |
| 205 | nsd-nasal | 1 |
| 206 | o-linked-n-acetyl | 1 |
| 207 | of.inhaled | 1 |
| 208 | omecamtiv | 26 |
| 209 | oral-loaded | 5 |
| 210 | oral/intravenous | 4 |
| 211 | orthoclone | 1 |
| 212 | parentally-administered | 1 |
| 213 | pareteral | 1 |
| 214 | particle-inhaled | 1 |
| 215 | patient-choice-facilitated | 1 |
| 216 | pb-stabilized | 1 |
| 217 | perindopril/ | 1 |
| 218 | peritendonous | 2 |
| 219 | phenylacetyl | 1 |
| 220 | pioglitazone→exenatide | 1 |
| 221 | placebo.additional | 1 |
| 222 | placebo/ | 2 |
| 223 | pmf/ | 1 |
| 224 | poly-n-acetyl | 3 |
| 225 | polycarbonate- | 1 |
| 226 | polyenteric-coated | 1 |
| 227 | ppia+oral | 1 |
| 228 | pre-junctional | 1 |
| 229 | precesarean | 1 |
| 230 | premedication+in | 4 |
| 231 | prolonged-action | 1 |
| 232 | prrsv+pcv2 | 1 |
| 233 | q10-containing | 1 |
| 234 | qi-zhi | 1 |
| 235 | quinazoline-based | 1 |
| 236 | rapid-and | 3 |
| 237 | recemic | 1 |
| 238 | recrystallised | 1 |
| 239 | reninintracellular | 2 |
| 240 | rfviii-lip | 1 |
| 241 | ring-fused | 9 |
| 242 | rxr-selective | 2 |
| 243 | s=3 | 2 |
| 244 | salm/fp+as-needed | 1 |
| 245 | same-potency | 1 |
| 246 | self-injectable | 3 |
| 247 | shenqi | 49 |
| 248 | short-/long-acting | 1 |
| 249 | sitagliptin→exenatide | 1 |
| 250 | sometribove | 3 |
| 251 | spun-cast | 1 |
| 252 | standard-titration | 5 |
| 253 | streptavidin- | 1 |
| 254 | studies.nebulized | 1 |
| 255 | sub-anesthetic | 1 |
| 256 | subantimicrobial-dose | 5 |
| 257 | subdissociative-dose | 3 |
| 258 | super-high-potent | 1 |
| 259 | superpotent | 6 |
| 260 | sutcutaneous | 1 |
| 261 | sympatheticomimetics | 1 |
| 262 | t2r38-directed | 1 |
| 263 | tci-delivered | 3 |
| 264 | tetrasulfide-containing | 1 |
| 265 | tissue-cultured | 2 |
| 266 | tomato-sourced | 1 |
| 267 | topical/systemic | 1 |
| 268 | tramadol/ | 2 |
| 269 | traumatic-induced | 1 |
| 270 | treadmill-running | 1 |
| 271 | triaromatic | 3 |
| 272 | trimethoprim- | 3 |
| 273 | u.k.-licensed | 1 |
| 274 | ultra-laba/ | 1 |
| 275 | ultrapotent | 3 |
| 276 | umuline | 2 |
| 277 | uv-only | 4 |
| 278 | uvb+ | 1 |
| 279 | valmet | 1 |
| 280 | varving | 1 |
| 281 | visit/systemic | 1 |
| 282 | water-dissolved | 1 |
| 283 | xiongbai | 2 |
| 284 | zaizao | 1 |
| 285 | β-agonist/inhaled | 1 |
| 286 | β2-agonist/inhaled | 3 |
| 287 | μ-agonist | 1 |
| 288 | μ-opioid-antagonist | 1 |
| 289 | ≥50μg | 1 |
| 290 | ▾ | 1 |
| 1 | uvb+ | 1 |
| 2 | mmf+ | 1 |
| 3 | 5,10,15,20- | 1 |
| 4 | polycarbonate- | 1 |
| 5 | trimethoprim- | 3 |
| 6 | streptavidin- | 1 |
| 7 | anti-tnf-α- | 1 |
| 8 | 5β- | 1 |
| 9 | 3,4-d. | 1 |
| 10 | ultra-laba/ | 1 |
| 11 | aminoglycoside/ | 4 |
| 12 | cefepime/ | 1 |
| 13 | pmf/ | 1 |
| 14 | levonorgestrel/ | 1 |
| 15 | perindopril/ | 1 |
| 16 | tramadol/ | 2 |
| 17 | fentanyl/ | 2 |
| 18 | imipenem/ | 1 |
| 19 | placebo/ | 2 |
| 20 | 1:100,000 | 105 |
| 21 | 1:200,000 | 79 |
| 22 | 1:50,000 | 7 |
| 23 | 1:80,000 | 12 |
| 24 | 1:2,000 | 1 |
| 25 | 1/100.000 | 1 |
| 26 | 1:100.000 | 3 |
| 27 | 1:200.000 | 2 |
| 28 | 1:100000 | 4 |
| 29 | 1:200000 | 2 |
| 30 | 1:80000 | 3 |
| 31 | 1:100.100 | 1 |
| 32 | an1/a20 | 2 |
| 33 | 5-c21 | 1 |
| 34 | 5c21 | 2 |
| 35 | 15222 | 1 |
| 36 | prrsv+pcv2 | 1 |
| 37 | cholestane-3 | 1 |
| 38 | isrctn63818313 | 1 |
| 39 | s=3 | 2 |
| 40 | 40/4.5 | 2 |
| 41 | blp25 | 1 |
| 42 | 17-alpha | 12 |
| 43 | recemic | 1 |
| 44 | hyodemic | 1 |
| 45 | topical/systemic | 1 |
| 46 | visit/systemic | 1 |
| 47 | anti-xerostomic | 1 |
| 48 | anabolic-androgenic | 34 |
| 49 | anabolic/androgenic | 1 |
| 50 | 17-ketogenic | 2 |
| 51 | triaromatic | 3 |
| 52 | sub-anesthetic | 1 |
| 53 | broncholitic | 1 |
| 54 | isosmotic | 6 |
| 55 | 200-mcg/d | 1 |
| 56 | tomato-sourced | 1 |
| 57 | traumatic-induced | 1 |
| 58 | oral-loaded | 5 |
| 59 | salm/fp+as-needed | 1 |
| 60 | fortifed | 1 |
| 61 | anesthesiologist-managed | 3 |
| 62 | inhaled | 6,234 |
| 63 | particle-inhaled | 1 |
| 64 | criteria.inhaled | 1 |
| 65 | of.inhaled | 1 |
| 66 | costs.inhaled | 2 |
| 67 | /inhaled | 3 |
| 68 | bronchodilator/inhaled | 1 |
| 69 | -agonist/inhaled | 1 |
| 70 | beta2-agonist/inhaled | 1 |
| 71 | β2-agonist/inhaled | 3 |
| 72 | β-agonist/inhaled | 1 |
| 73 | hydrofluoroalkane-propelled | 5 |
| 74 | chlorofluorocarbon-propelled | 2 |
| 75 | gallium-doped | 1 |
| 76 | non-anaesthesiologist-administered | 2 |
| 77 | endoscopist-administered | 3 |
| 78 | iv-administered | 4 |
| 79 | parentally-administered | 1 |
| 80 | intra-mammary-administered | 1 |
| 81 | tci-delivered | 3 |
| 82 | locally-delivered | 1 |
| 83 | beef-flavored | 1 |
| 84 | tissue-cultured | 2 |
| 85 | desflurane-based | 3 |
| 86 | quinazoline-based | 1 |
| 87 | 1,2,3-triazolium-based | 1 |
| 88 | recrystallised | 1 |
| 89 | aerosolised | 18 |
| 90 | nebulised | 332 |
| 91 | u.k.-licensed | 1 |
| 92 | fixed-dosed | 1 |
| 93 | ring-fused | 9 |
| 94 | nbp-stimulated | 1 |
| 95 | care-co-formulated | 1 |
| 96 | polyenteric-coated | 1 |
| 97 | patient-choice-facilitated | 1 |
| 98 | everolimus-facilitated | 1 |
| 99 | t2r38-directed | 1 |
| 100 | hepatocyte-targeted | 1 |
| 101 | mpla-adjuvanted | 1 |
| 102 | carbon-supported | 4 |
| 103 | 16-heterosubstituted | 1 |
| 104 | 2-ohe-derived | 1 |
| 105 | water-dissolved | 1 |
| 106 | nonpreserved | 7 |
| 107 | lipid-normalized | 1 |
| 108 | pb-stabilized | 1 |
| 109 | aerosolized | 264 |
| 110 | nebulized | 658 |
| 111 | jet-nebulized | 1 |
| 112 | studies.nebulized | 1 |
| 113 | cyp3a4-catalyzed | 1 |
| 114 | 25-week-old | 1 |
| 115 | rapid-and | 3 |
| 116 | immediate-and | 1 |
| 117 | alphaxaloneand | 1 |
| 118 | niacin-bound | 1 |
| 119 | alkaloide | 1 |
| 120 | aminomonosaccharide | 1 |
| 121 | pioglitazone→exenatide | 1 |
| 122 | sitagliptin→exenatide | 1 |
| 123 | cfc-free | 6 |
| 124 | initiator-free | 1 |
| 125 | flexible-dosage | 1 |
| 126 | self-injectable | 3 |
| 127 | auto-injectable | 1 |
| 128 | naproxen/esomeprazole | 17 |
| 129 | cholestane | 1 |
| 130 | 3β-hydroxy-5-ene | 1 |
| 131 | helene | 2 |
| 132 | dehydropydine | 1 |
| 133 | extra-fine | 18 |
| 134 | extrafine | 35 |
| 135 | microfine | 2 |
| 136 | micro-crystalline | 1 |
| 137 | umuline | 2 |
| 138 | non-epinephrine | 2 |
| 139 | cephalexine | 1 |
| 140 | orthoclone | 1 |
| 141 | matrix-type | 5 |
| 142 | instant-release | 1 |
| 143 | biorelease | 1 |
| 144 | subdissociative-dose | 3 |
| 145 | antimicrobial-dose | 1 |
| 146 | subantimicrobial-dose | 5 |
| 147 | low-to-medium-dose | 2 |
| 148 | bolus-dose | 8 |
| 149 | high-bolus-dose | 1 |
| 150 | ketamine-low-dose | 1 |
| 151 | midazolam/low-dose | 1 |
| 152 | multiple-course | 2 |
| 153 | inhalative | 31 |
| 154 | -perioperative | 1 |
| 155 | lipid-deficient/evaporative | 1 |
| 156 | neuroactive | 78 |
| 157 | beta-2-selective | 1 |
| 158 | rxr-selective | 2 |
| 159 | sometribove | 3 |
| 160 | 35-mcg | 1 |
| 161 | 0.25mg/kg | 3 |
| 162 | 1-μg/kg | 1 |
| 163 | 10-60-mg | 1 |
| 164 | 3.3-mg | 1 |
| 165 | 0.25-mg | 2 |
| 166 | 0.075-mg | 4 |
| 167 | 350ng | 1 |
| 168 | langchuang | 1 |
| 169 | inhaling | 113 |
| 170 | q10-containing | 1 |
| 171 | tetrasulfide-containing | 1 |
| 172 | cysteine-containing | 3 |
| 173 | hydroquinone-containing | 2 |
| 174 | bpo-containing | 1 |
| 175 | treadmill-running | 1 |
| 176 | applicating | 1 |
| 177 | long-/ultra-long-acting | 1 |
| 178 | non-long-acting | 1 |
| 179 | short-/long-acting | 1 |
| 180 | depot/long-acting | 1 |
| 181 | ezh2-targeting | 1 |
| 182 | varving | 1 |
| 183 | essaying | 1 |
| 184 | 150-µg | 1 |
| 185 | ≥50μg | 1 |
| 186 | 1.5μg | 1 |
| 187 | 75μg | 2 |
| 188 | 1'-oh | 1 |
| 189 | nonprescription-strength | 1 |
| 190 | hf+i | 1 |
| 191 | xiongbai | 2 |
| 192 | bufei | 12 |
| 193 | qi-zhi | 1 |
| 194 | shenqi | 49 |
| 195 | every-two-week | 1 |
| 196 | 150μmol/l | 2 |
| 197 | 2+2l | 1 |
| 198 | intraoperative-intrathecal | 1 |
| 199 | generic-original | 1 |
| 200 | pre-junctional | 1 |
| 201 | placebo.additional | 1 |
| 202 | pareteral | 1 |
| 203 | ppia+oral | 1 |
| 204 | non-oral | 39 |
| 205 | inhaled/oral | 2 |
| 206 | intra-nasal | 4 |
| 207 | nsd-nasal | 1 |
| 208 | intranasal | 1,329 |
| 209 | inhaled/intranasal | 1 |
| 210 | intrabursal | 7 |
| 211 | multi-barrel | 1 |
| 212 | bioavail | 2 |
| 213 | hpol | 5 |
| 214 | glycosylphosphatidyl | 1 |
| 215 | 1,1,3,3-tetramethyl | 1 |
| 216 | n'-dialkyl | 1 |
| 217 | methylcyclopentadienyl | 1 |
| 218 | 2,2-diphenyl-1-picryl | 6 |
| 219 | 4'-o-glucosyl | 1 |
| 220 | -o-apiosyl | 1 |
| 221 | -o-xylosyl | 2 |
| 222 | o-linked-n-acetyl | 1 |
| 223 | poly-n-acetyl | 3 |
| 224 | phenylacetyl | 1 |
| 225 | 0.3ppm | 1 |
| 226 | approach-short-term | 1 |
| 227 | precesarean | 1 |
| 228 | antiprogestagen | 2 |
| 229 | meta-analysis.when | 1 |
| 230 | heliox®-driven | 1 |
| 231 | premedication+in | 4 |
| 232 | 0.5mg/kg/min | 1 |
| 233 | 0.2-μg/kg/min | 1 |
| 234 | karyopherin | 1 |
| 235 | anti-progestin | 4 |
| 236 | lipid-emulsion | 2 |
| 237 | 16β-hydroxylation | 2 |
| 238 | standard-titration | 5 |
| 239 | prolonged-action | 1 |
| 240 | chongcao | 5 |
| 241 | zaizao | 1 |
| 242 | 'staccato | 1 |
| 243 | 17-keto | 2 |
| 244 | rfviii-lip | 1 |
| 245 | 3mix-mp | 1 |
| 246 | anti-meth/amp | 1 |
| 247 | intra-testicular | 1 |
| 248 | reninintracellular | 2 |
| 249 | co-regulator | 1 |
| 250 | islas | 1 |
| 251 | sympatheticomimetics | 1 |
| 252 | 9-cis | 12 |
| 253 | glycozaminoglycans | 1 |
| 254 | acylureido-penicillins | 1 |
| 255 | sutcutaneous | 1 |
| 256 | antiandrogenous | 1 |
| 257 | mtx+intravenous | 1 |
| 258 | oral/intravenous | 4 |
| 259 | peritendonous | 2 |
| 260 | valmet | 1 |
| 261 | caveolin-3-dependent | 1 |
| 262 | high-potent | 2 |
| 263 | super-high-potent | 1 |
| 264 | ultrapotent | 3 |
| 265 | superpotent | 6 |
| 266 | spun-cast | 1 |
| 267 | mild/modest | 1 |
| 268 | non-anaesthesiologist | 2 |
| 269 | alpha/beta-agonist | 1 |
| 270 | μ-agonist | 1 |
| 271 | d2-antagonist | 1 |
| 272 | ck2-antagonist | 1 |
| 273 | eta-antagonist | 1 |
| 274 | μ-opioid-antagonist | 1 |
| 275 | 50iu | 1 |
| 276 | 1/v | 1 |
| 277 | l/v | 2 |
| 278 | itm/iv | 4 |
| 279 | omecamtiv | 26 |
| 280 | ad35-grin/env | 4 |
| 281 | same-potency | 1 |
| 282 | uv-only | 4 |
| 283 | inhalatory | 13 |
| 284 | enhanced-affinity | 5 |
| 285 | 1'-hydroxy | 3 |
| 286 | 1-hydroxy | 2 |
| 287 | estrone:16α-hydroxy | 1 |
| 288 | -3β-hydroxy | 1 |
| 289 | 17-α | 5 |
| 290 | ▾ | 1 |